Regarding ALK-positive NSCLC, the most relevant phase II trials evaluating the use of alectinib as neoadjuvant or perioperative therapy are NAUTIKA1 and ALNEO [46,67]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.